| 0.8225 0 (0%) | 04-28 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
IMV Inc., a clinical-stage biotechnology company founded in 2000 and based in Dartmouth, Canada, is focused on immuno-oncology. The firm develops a range of therapeutic candidates for solid and hematological cancers utilizing its proprietary DPX immune-educating technology platform. Its primary drug candidate, maveropepimut-S, is a DPX-based immunotherapy engineered to specifically target survivin-expressing cells. This compound is currently in Phase II clinical trials for several cancer types, including diffuse large B cell lymphoma, ovarian cancer, bladder cancer, liver cancer, and tumors exhibiting high microsatellite instability. Maveropepimut-S is also being investigated in a Phase I clinical trial for breast cancer. The company's pipeline further includes DPX-SurMAGE, which is in Phase I development for bladder cancer, as well as DPX-COVID-19 and DPX-RSV, both aimed at addressing infectious diseases. IMV Inc. was previously known as Immunovaccine Inc. before changing its name in May 2018.
Wed, 02 Sep 2026
IMV Inc. (IMV) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Mon, 07 Apr 2025
Change at the top at IMV Technologies Group: Oliver Kohlhaas succeeds Alain de Lambilly as CEO - 3tres3.com
Tue, 13 Feb 2024
BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets - Pharmaceutical Technology
Mon, 27 Nov 2023
Toyota Launches IMV 0 in Thailand Providing Mobility to Make People's Lives Better through Customizability - トヨタ自動車株式会社 公式企業サイト
Mon, 08 May 2023
IMV Inc. (TSX: IMV), CCAA - Insolvency Insider Canada
Mon, 01 May 2023
Court grants creditor protection to N.S. company developing cancer treatments - CBC
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|